Elite Pharmaceuticals Inc. (OTCMKTS:ELTP – Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $0.4710, but opened at $0.4508. Elite Pharmaceuticals shares last traded at $0.4784, with a volume of 23,382 shares changing hands.
Elite Pharmaceuticals Stock Performance
The company has a current ratio of 8.04, a quick ratio of 6.34 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $521.24 million, a PE ratio of 48.56 and a beta of 0.32. The stock’s 50 day moving average price is $0.53 and its two-hundred day moving average price is $0.58.
About Elite Pharmaceuticals
Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.
Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.
See Also
- Five stocks we like better than Elite Pharmaceuticals
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- How the Rich Retire
Receive News & Ratings for Elite Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elite Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
